Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea.

ABSTRACT:

Background

Clinical outcomes of new-generation drug-eluting stents (DES), Everolimus-eluting stent (EES) or Resolute zotarolimus-eluting stent (R-ZES), have been reported. However, angiographic follow-up data of new-generation DES are limited, especially in Asians. We investigated the angiographic and clinical outcomes of EES and R-ZES in a real-world setting of Korean patients.

Methods

Angiographic and clinical outcomes of 679 patients (866 lesions) who had been treated with EES or R-ZES from Jun 2008 to May 2010 were evaluated. The primary analysis was to compare in-segment late loss at 9 months and the secondary analyses were to compare the clinical outcomes.

Results

In-segment late loss at 9-month follow-up angiography was 0.23?±?0.52 mm for EES and 0.29?±?0.64 mm for R-ZES (p?=?0.248). In addition, the rate of binary restenosis did not show between-group differences (5.8% vs. 6.8% for EES and R-ZES, respectively, p?=?0.716). During a median follow-up of 33 months, there were no significant differences in Kaplan-Meier estimates of target lesion failure (TLF) (7.5% vs. 7.9% for EES and R-ZES, respectively, p?=?0.578) and patient-oriented composite outcomes (POCO including all-cause death, any myocardial infarction, and any revascularization, 22.8% vs. 20.1%, p?=?0.888). The adjusted hazard ratios for TLF and POCO were 0.875 (95% CI 0.427?-?1.793; p?=?0.715) and 1.029 (95% CI 0.642?-?1.650; p?=?0.904), respectively, for EES over R-ZES in the propensity score matched group analysis.

Conclusions

In Korean patients undergoing new-generation DES implantation for coronary artery disease, EES and R-ZES showed similar angiographic outcomes at 9 months and comparable clinical outcomes during 2.8 years of median follow-up.

SUBMITTER: Lee JM 

PROVIDER: S-EPMC3846488 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature